WKL:EURONEXT AMSTERDAMWolters Kluwer N.V. Analysis
Data as of 2026-03-10 - not real-time
€67.16
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Wolters Kluwer (WKL.AS) trades at €67.16, sitting above its 20‑day SMA (≈€64.7) but well below the 50‑day (≈€75.4) and 200‑day (≈€106.3) averages, confirming a bearish technical backdrop. The RSI of 44.8 signals modest momentum, while the MACD histogram is positive, giving a bullish signal despite the overall bearish trend. Price action hovers near the identified resistance of €71.0 and comfortably above the support at €59.0. Fundamentally, the stock appears cheap on a PE basis (11.9× vs. industry 29.4×) and offers a solid dividend yield of 3.67% with a 43% payout ratio, but the DCF fair value of €49.4 suggests it is priced above intrinsic estimates. Recent material news includes the launch of the “Libra” legal‑tech platform and a series of share‑buyback programmes in January‑February 2026, both of which signal management confidence and could provide short‑term price support.
Overall, the valuation sits in a fair range with a tilt toward value characteristics, the dividend appears sustainable given cash flow coverage, and the primary risks stem from high leverage (debt‑to‑equity > 600) and elevated short‑term volatility (≈56% 30‑day).
Overall, the valuation sits in a fair range with a tilt toward value characteristics, the dividend appears sustainable given cash flow coverage, and the primary risks stem from high leverage (debt‑to‑equity > 600) and elevated short‑term volatility (≈56% 30‑day).
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with bearish SMA alignment
- Positive MACD histogram indicating limited upside
- Recent share‑buyback activity supporting price floor
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation upside vs. industry peers (low PE)
- Product innovation (Libra platform) expanding revenue streams
- Attractive dividend yield and ongoing buyback programme
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- High leverage and low ROE limiting growth potential
- Sustainable dividend supported by cash flow
- Diversified global exposure mitigating single‑market risk
Key Metrics & Analysis
Financial Health
Revenue Growth1.60%
Profit Margin21.36%
P/E Ratio11.9
ROE111.65%
ROA10.01%
Debt/Equity623.06
P/B Ratio19.0
Op. Cash Flow€1.7B
Free Cash Flow€1.0B
Industry P/E29.4
Technical Analysis
TrendBearish
RSI44.8
Support€59.00
Resistance€70.98
MA 20€64.70
MA 50€75.40
MA 200€106.27
MACDBullish
VolumeStable
Fear & Greed Index76.91
Valuation
Fair Value€49.37
Target Price€114.71
Upside/Downside70.81%
GradeFair
TypeValue
Dividend Yield3.67%
Risk Assessment
Beta0.03
Volatility56.34%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.